Press Releases

Osteoarthritis Market Analysis Key Trends, Drivers and Growth Forecast (2024 – 2032)

The osteoarthritis market is expected to grow significantly, from USD 8.60 billion in 2023 to approximately USD 19.15 billion by 2032, reflecting a compound annual growth rate (CAGR) of 8.4% during the forecast period from 2024 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5136

Osteoarthritis Market Overview: Key Insights and Trends

In 2023, knee osteoarthritis was the leading cause of wear and tear in the market, accounting for more than 49% of the total share. Imaging tests played a dominant role in diagnosing the condition, holding a significant market share. North America stood out with a substantial 38% market share in the same year. According to the Centers for Disease Control and Prevention (CDC), osteoarthritis made up 2.5% of all health issues in 2023, contributing to 20% of the overall burden of musculoskeletal conditions.

Globally, osteoarthritis affects around 3.3% to 3.6% of people and is a major cause of disability for approximately 43 million individuals, ranking it as the 11th most disabling condition worldwide. In the United States, around 80% of people aged 65 and older show signs of osteoarthritis on X-rays, but only 60% experience symptoms. This discrepancy occurs because changes observed in X-ray images do not always directly correlate with the joint pain a person feels.

Osteoarthritis is a common joint disorder where the cartilage that protects the bones wears down over time. This can cause pain, stiffness, and reduced flexibility in affected joints, such as the hands, hips, and knees.

Key Factors Contributing to Osteoarthritis:

  • Age: The risk of developing osteoarthritis increases with age.
  • Sex: Women are more likely to develop osteoarthritis after the age of 50 compared to men.
  • Obesity: Excess weight puts added stress on joints, especially those that bear weight, such as the knees and hips, increasing the risk of osteoarthritis. Additionally, obesity may lead to metabolic changes that further raise the risk.
  • Genetics: A family history of osteoarthritis increases the likelihood of developing the condition.

In 2020-21, approximately $4.3 billion was spent on osteoarthritis care, representing 2.9% of total healthcare spending and 29% of the spending on all musculoskeletal conditions.

While osteoarthritis is not curable, proper treatment is essential to manage symptoms, improve joint function, and enhance quality of life. Treatment strategies include lifestyle changes like exercise and weight management, medications to manage pain and inflammation, and, in some cases, surgery. Early diagnosis and intervention are critical to slowing disease progression and maintaining an active lifestyle.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/osteoarthritis-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5136

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.

Recent Posts

Kedrion Biopharma’s COAGADEX® Receives FDA Orphan Drug Designation for Acquired Factor X Deficiency (AFXD)

Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More

1 day ago

Benecard PBF and DecisionRX Join Forces to Personalize and Optimize Pharmacy Benefits

enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More

1 day ago

Four Resilient Biotech Companies Making Waves in a Challenging Market

In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More

1 day ago

Natera Launches TEODOR Trial in Partnership with ABCSG to Advance Personalized Breast Cancer Treatment

cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More

1 day ago

Interventional Radiology Market: Size, Growth, and Leading Companies Driving Innovation

The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More

1 day ago

Physical Therapy Market Growth and Leading Companies Driving Innovation

The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More

1 day ago